Reviewing Palvella Therapeutics (PVLA) and Its Rivals

Palvella Therapeutics (NASDAQ:PVLA) is one of 1,068 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its rivals? We will compare Palvella Therapeutics to related businesses based on the strength of its earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Insider and Institutional Ownership

40.1% of Palvella Therapeutics shares are owned by institutional investors. Comparatively, 44.1% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 6.4% of Palvella Therapeutics shares are owned by insiders. Comparatively, 13.6% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Palvella Therapeutics and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Palvella Therapeutics	$42.81 million	-$24.54 million	-1.60
Palvella Therapeutics Competitors	$9.54 billion	$137.14 million	-7.35

Palvella Therapeutics’ rivals have higher revenue and earnings than Palvella Therapeutics. Palvella Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Palvella Therapeutics and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palvella Therapeutics	0	0	4	0	3.00
Palvella Therapeutics Competitors	8156	21815	49621	1310	2.54

Palvella Therapeutics presently has a consensus target price of $40.33, indicating a potential upside of 108.87%. As a group, “Pharmaceutical preparations” companies have a potential upside of 244.25%. Given Palvella Therapeutics’ rivals higher probable upside, analysts plainly believe Palvella Therapeutics has less favorable growth aspects than its rivals.

Profitability

This table compares Palvella Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Palvella Therapeutics	N/A	-80.93%	-59.55%
Palvella Therapeutics Competitors	-3,409.82%	-235.83%	-32.89%

Risk & Volatility

Palvella Therapeutics has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Comparatively, Palvella Therapeutics’ rivals have a beta of 3.66, suggesting that their average stock price is 266% more volatile than the S&P 500.

Summary

Palvella Therapeutics rivals beat Palvella Therapeutics on 8 of the 13 factors compared.

About Palvella Therapeutics

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.